Antibody Information
General Information of This Antibody
| Antibody ID | ANI0XNVVP |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | C-1131 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antigen Name | Kita-kyushu lung cancer antigen 1 (CT83) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
1131-MMAE [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 58.80% (Day 21) | Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.3 mg/kg.
|
||||
| In Vivo Model | Gastric cancer CDX model | ||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 80.36% (Day 21) | Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 1 mg/kg.
|
||||
| In Vivo Model | Gastric cancer CDX model | ||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 83.05% (Day 5) | Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 3 mg/kg.
|
||||
| In Vivo Model | Gastric cancer CDX model | ||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.92% (Day 21) | Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 2 mg/kg.
|
||||
| In Vivo Model | Gastric cancer CDX model | ||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
3.87 nM
|
Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Gastric signet ring cell adenocarcinoma | NUGC-4 cells | CVCL_3082 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.26 nM
|
Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
786.00 nM
|
Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Gastric carcinoma | HGC-27 cells | CVCL_1279 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.